Express Scripts (ESRX) 69.65 $ESRX The Economist

New Post Public Reply Private Reply Replies (0) Message Board

Sep 22, 2016 at 1:22 AM

Express Scripts (ESRX) 69.65 $ESRX

The Economist Presents: "The War on Cancer: Scaling Progress"
PR Newswire - Thu Sep 15, 9:00AM CDT
The Economist Events will hold the second annual War on Cancer Forum, on the theme of "Scaling Progress" on September 28th 2016 at the Hyatt Regency Hotel in Boston.
ESRX: 69.65 (+0.40)

After Yesterday's Decline of 2.02%, Express Scripts Offers Investors Better Value
Comtex SmarTrend(R) - Tue Sep 13, 4:12PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $70.64 to a high of $71.51. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $70.72 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 69.65 (+0.40)

Express Scripts Set to Possibly Rebound After Yesterday's Selloff of 2.02%
Comtex SmarTrend(R) - Tue Sep 13, 4:10PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $70.64 to a high of $71.51. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $70.72 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 69.65 (+0.40)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Express Scripts Holding Company for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Fri Sep 09, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / September 9, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Express Scripts Holding Company (NASDAQ: ESRX).
ANTM: 128.59 (+2.83), ESRX: 69.65 (+0.40)

Express Scripts Launches Inflammatory Conditions Care Value Program(SM), Making America's Costliest Medication Class More Affordable
PR Newswire - Thu Sep 08, 6:00AM CDT
Express Scripts (NASDAQ: ESRX) today launched its Inflammatory Conditions Care Value Programâ", a comprehensive approach to control costs and improve care for people with inflammatory conditions like rheumatoid arthritis, psoriasis and Crohn's Disease.
ESRX: 69.65 (+0.40)

Cost Effective Benefits Of New "First Step" Infertility Treatment Continue
BusinessWire - Wed Sep 07, 6:00AM CDT
Despite the recent findings that enrollment in the Affordable Care Act's (ACA) insurance exchanges has fallen, Conceivex said today that couples across the country continue to be able to take advantage of a new, insurance-covered "first step" therapy to overcome infertility.
ESRX: 69.65 (+0.40)

Express Scripts Holding Company to Present at an Upcoming Conference
PR Newswire - Thu Sep 01, 1:38PM CDT
Express Scripts Holding Company (Nasdaq: ESRX) (the "Company" or "Express Scripts"

announced today that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 1:00 p.m. Eastern Time (12:00 p.m. Central Time).
ESRX: 69.65 (+0.40)

Express Scripts' New Program to Lower Diabetes Care Costs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:00AM CDT
Express Scripts Holding Company (ESRX) has launched the Diabetes Care Value Program to lower costs for patients and provide better care.
ESRX: 69.65 (+0.40), ANIP: 65.12 (+0.28), LLY: 80.87 (+0.99)

Express Scripts Launches Diabetes Care Value Programâ", Guaranteeing More Affordable, Higher-Quality Diabetes Care
PR Newswire - Tue Aug 30, 11:01PM CDT
Express Scripts (NASDAQ: ESRX) today announced the launch of its Diabetes Care Value Programâ", the industry's most comprehensive approach to improve pharmacy care while controlling plan costs for people with diabetes.
ESRX: 69.65 (+0.40)

Blog Coverage Walgreens Boots Alliance Partners with Prime Therapeutics for a Bigger Slice of the Prescription Drug Market
ACCESSWIRE - Tue Aug 30, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 30, 2016 / Active Wall St. blog coverage looks at the headline from Walgreens Boots Alliance, Inc. (NASDAQ: WBA) announced a strategic partnership with pharmacy benefit manager (PBM) Prime Therapeutics on August 29, 2016 to form a new retail pharmacy network that combines mail order and speciality pharma business. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
ESRX: 69.65 (+0.40), WBA: 80.58 (-0.06), UNH: 139.91 (+2.44), RAD: 8.10 (+0.06)

Mylan launching cheaper, generic version of EpiPen
By LINDA A. JOHNSON and TOM MURPHY - AP - Mon Aug 29, 4:20PM CDT
The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues — and looming competition threatens its near-monopoly.
ESRX: 69.65 (+0.40), MYL: 41.91 (+0.65)

Stock Market News for August 26, 2016
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:09AM CDT
Benchmarks finished in the red on Thursday as investors refrained from making big bets ahead of Fed Chief Janet Yellen’s speech at Jackson Hole, Wyoming today
MNK: 74.09 (-0.01), TSLA: 205.22 (+0.58), ENDP: 20.09 (-0.20), F: 12.09 (+0.09), MDT: 87.14 (+0.78), GME: 28.13 (+0.41), MYL: 41.91 (+0.65), PDCO: 46.80 (+0.57), TIF: 72.27 (+0.74), BA: 130.56 (+2.77), ESRX: 69.65 (+0.40), STJ: 79.44 (+0.55), SSYS: 22.22 (+0.23), TECD: 86.19 (+1.11), ADSK: 71.69 (+2.90)

Mylan boosts EpiPen patient programs, doesn't budge on price
By LINDA A. JOHNSON and TOM MURPHY - AP - Thu Aug 25, 4:45PM CDT
The maker of EpiPens offered patients more help to pay for its costly emergency allergy shots but didn't budge Thursday on the $608 price.
ESRX: 69.65 (+0.40), VRX: 26.97 (+0.64), MYL: 41.91 (+0.65), VRX.TO: 35.34 (+0.51)

Look for Shares of Express Scripts to Potentially Rebound after Yesterday's 4.00% Sell Off
Comtex SmarTrend(R) - Thu Aug 25, 11:59AM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $73.01 to a high of $76.08. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $76.00 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 69.65 (+0.40)

SmarTrend Watching for Potential Rebound in Shares of Express Scripts After 4.00% Loss
Comtex SmarTrend(R) - Thu Aug 25, 11:57AM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $73.01 to a high of $76.08. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $76.00 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 69.65 (+0.40)

PharmCo to Offer Emergency Prescriptions to Residents in Louisiana Flood Zone
Marketwired - Thu Aug 25, 9:10AM CDT
MIAMI, FL--(Marketwired - August 25, 2016) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, has begun offering emergency prescription services to Louisiana Flood Zone residents.
ESRX: 69.65 (+0.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Identity Safety Boost: Veteran Launches AIIS

Reckoning with Identity Theft on a New Scale Eric Haller spent decades in the thick of fraud prevention, working at both Experian and TransUnion. But it wasn't until his own identity was swiped clean that the gravity of the issue hit home. Spurred by this personal crisis, he's now spearheading the American Institute for Identity Safety (AIIS), putting a strongfoot forward...

Deadline Nears for Everest Group Class Action Plaintiffs

Everest Group Faces Heavy Litigation Alright, folks, grab your mugs of caffeine and let's dive right into the mess Everest Group, Ltd. has found itself in. The clock is ticking for investors who've taken a punch in the gut between February 8, 2024, and October 27, 2025, courtesy of NYSE: EG. Lawyers are on the chase, and come December 28, 2026, the window to spearhead a...

PROYA Skincare Expands to Ulta: A Scientific Ambition

A New Chapter for PROYA Bet you didn't see this one coming: a leading Chinese beauty brand, PROYA, is throwing its hat into the North American skincare ring, rolling out its science-backed skincare line nationwide at Ulta Beauty. The same brand that's been big news across Asia is now setting its sights on the U.S. with a stunning array of products that don't just promise...

Smirnoff and Broski Unleash Quirky Holiday Merch

Surprise in a Box: A Holiday Twist Who knew that a ukulele box would end up sparking more holiday joy than the instrument itself? Smirnoff Ice and social media sensation Brittany Broski are giving us a holiday roll-out that takes a good look at the absurd and runs with it. Instead of strings and melodies, you open that box to find a Smirnoff Ice bottle ready to chill your...

Corteva's Q3 Performance: Navigating Market Turbulence

Let's tear into Corteva's third-quarter dance with the market—nothing like a little tussle with headwinds to keep things interesting. Released on November 11, 2026, their financial results reveal a company weathering a rough patch but still managing to hold its head above water. Struggling Sales and Competitive Pressures When it rains, it pours, and for Corteva, the...

Compass Faces Legal Heat Over Accelerated Merger Closing

A Storm Brews Over Compass's Hasty Merger Actions Ah, the unpredictable world of mergers and acquisitions, where timelines often feel like they're written in sand, easy to shift with the tides. Today, we untangle the drama swirling around Compass, Inc. (NYSE: COMP) and its speedy merger with Anywhere Real Estate, a tale that's leaving investors with a taste that's more...

Helix Raises $6.2M, Tackles AI Fraud with Voice Tech

A New Era of Voice-Driven Verification Blockchain and biometrics? Ancient history. Today, Helix drops a game-changer into the digital verification scene, raising a hefty $6.2 million in pre-seed capital. They're tackling the AI age's rampant bot issues with some slick voice-based magic. Imagine biometric-level security from a four-second challenge—not a bad little trick...

Olight's Oclip 2: Illuminating the Auto World at SEMA

The Oclip 2 Series: A Game-Changer for Mechanics When Olight sets up shop at the SEMA Show 2026, they're not just pulling a rabbit out of the hat. Nope, they're rolling out the Oclip 2 Series, a lighting tool engineered for those insane angles and shadowy corners under a mechanic's hood. If the idea of a flexible, hands-free light that finally adapts to the fiddly demands...

LaserAway Celebrates 20 Years with New Clinic in WA

Expanding the Beauty Service Frontier LaserAway just cut the ribbon on its latest clinic, planting its flag in Lynnwood, WA. This isn't just any opening—it's the 242nd clinic for the nation's aesthetic dermatology heavyweight, all in time for their 20th bash. We can brag about fancy office locales all we want, but 20 years without a single clinic shutdown in a cutthroat...

Noah's Q3 2026 Earnings: What Investors Should Watch

Anticipation Builds for Noah's Earnings Report A penny for your thoughts? More like a truckload for some insights on Noah Holdings (NYSE: NOAH). They’re taking the stage to drop their Q3 2026 earnings on November 24, after the markets put their feet up. If you're tracking global wealth managers, especially those dancing on the NYSE and the Hong Kong Stock Exchange...